News Headlines Article

Gilead hints at price of next-generation hepatitis C treatment
San Francisco Business Times

If you think Gilead Sciences Inc.’s blockbuster hepatitis C drug Sovaldi costs a lot, wait for this: A next-generation treatment that could win approval next month will cost even more, but under $100,000. The company points out that the new price tag is roughly as much as today’s Sovaldi treatments when all is said and done.

Although Gilead Executive Vice President Gregg Alton told Reuters that the Foster City-based company (NASDAQ: GILD) won’t give an exact price of the oral treatment, which combines Sovaldi with the Gilead-developed ledipasvir, he said it won’t carry a significant premium to the cost of treatment today.